In the future, studies with a larger sample size and an extended follow-up period are warranted to further evaluate the clinical efficacy of sintilimab combined with albumin-bound paclitaxel plus cisplatin in treating stage IB–IIIB NSCLC. The gene discussed is ALB; the disease is non-small cell lung carcinoma.